1. Home
  2. KOSS vs BTAI Comparison

KOSS vs BTAI Comparison

Compare KOSS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.85

Market Cap

43.6M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$2.09

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
BTAI
Founded
1953
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.6M
49.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KOSS
BTAI
Price
$4.85
$2.09
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$32.80
AVG Volume (30 Days)
25.6K
669.3K
Earning Date
10-30-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,493,080.00
$752,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$544.99
P/E Ratio
N/A
N/A
Revenue Growth
11.58
N/A
52 Week Low
$4.00
$1.17
52 Week High
$8.59
$9.26

Technical Indicators

Market Signals
Indicator
KOSS
BTAI
Relative Strength Index (RSI) 51.05 52.95
Support Level $4.81 $1.82
Resistance Level $4.99 $2.33
Average True Range (ATR) 0.19 0.17
MACD 0.04 0.05
Stochastic Oscillator 71.43 71.93

Price Performance

Historical Comparison
KOSS
BTAI

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: